This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Business Combination and completed private equityfinancing are structured to ensure total gross proceeds of a minimum of $180 million, which is expected to fund the combined company into 2026 based on current plans and estimates. NEW HOPE, Pa. and NEW YORK, July 05, 2022 (GLOBE NEWSWIRE) -- Orchestra BioMed™, Inc.
billion and ~$150 million in pro forma cash on the combined company balance sheet with a combined ~12% EBITDA margin 1 , and no debt or equityfinancing contemplated. Industry Leading Financial Profile : Estimated LTM combined revenue of $1.2
WSP expects 2026 Accretion 3 (as defined below) to be in mid-single digits once cost synergies are fully realized. 5 Expected cost synergies of a minimum of approximately US$25 million are expected to be achieved by the end of 2026, with 50% expected to be realized in 2025. Acquisition price represents 15.2x post-synergies.
Transaction Highlights Creation of one of Canada's largest, lowest cost and most profitable gold mines – combined Magino and Island Gold mines are expected to produce approximately 280,000 ounces in 2024 4 , and increase to over 400,000 ounces per year at first quartile costs, following the completion of the Phase 3+ Expansion in 2026.
The Facility consists of a $500 million unsecured revolving line of credit with an initial maturity in 2026, with two six-month extension options, and $310 million of term loans with maturities in 2026 through 2028. The Facility includes an accordion feature that allows the Company to increase the total potential capacity up to $1.25
Of most importance for financial institutions, the identified categories also include downstream activities such as “investments” (Category 15 of the GHG Protocol’s Scope 3 emissions categories), which would capture financed emissions ( i.e. , emissions from companies to which the financial institution provides debt or equityfinancing).
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content